dobutamin carino 500mg/50ml
carinopharm gmbh (8031371) - dobutaminhydrochlorid - infusionslösung - teil 1 - infusionslösung; dobutaminhydrochlorid (12890) 560 milligramm
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
dobutamin carino 500 mg/50 ml infusionslösung
carinopharm gmbh (8031371) - dobutaminhydrochlorid - infusionslösung - teil 1 - infusionslösung; dobutaminhydrochlorid (12890) 560 milligramm
octaplex 1000
octapharma gmbh (3237398) - blutgerinnungsfaktor ii; blutgerinnungsfaktor vii; blutgerinnungsfaktor ix vom menschen; blutgerinnungsfaktor x; plasmaprotein c vom menschen; plasmaprotein s vom menschen - pulver und lösungsmittel zur herstellung einer infusionslösung - teil 1 - pulver; blutgerinnungsfaktor ii (05482) 560 internationale einheit; blutgerinnungsfaktor vii (06225) 360 internationale einheit; blutgerinnungsfaktor ix vom menschen (03800) 800 internationale einheit; blutgerinnungsfaktor x (06226) 720 internationale einheit; plasmaprotein c vom menschen (10669) 520 internationale einheit; plasmaprotein s vom menschen (32012) 480 internationale einheit
dobutamin liquid fresenius 500 mg/50 ml infusionslösung
fresenius kabi deutschland gmbh (3003660) - dobutaminhydrochlorid - infusionslösung - dobutaminhydrochlorid (12890) 560 milligramm
alk-prick n 560 rattenhaare lösung
alk-abelló arzneimittel gmbh - rattenhaar-allergen - lösung - rattenhaar-allergen 1% (m/v)
alk-prick n 560 rattenhaare lösung
alk-abelló arzneimittel gmbh - rattenhaar-allergen - lösung - rattenhaar-allergen 5% (m/v)
alk-wässrig n 560 rattenhaare lösung
alk-abelló arzneimittel gmbh - rattenhaar-allergen - lösung - rattenhaar-allergen 1% (m/v)
flector plus tissugel putz
ibsa institut biochimique sa - diclofenacum epolaminum, heparinum natricum - putz - diclofenacum epolaminum 181 mg corresp. diclofenacum natricum 140 mg, heparinum natricum 5600 u.i., gelatina, povidonum k 90, sorbitolum liquidum non cristallisabile, kaolinum ponderosum, dinatrii edetas, acidum tartaricum, carmellosum natricum, natrii polyacrylas, aluminii glycinas, 1,3-butandiolum, polysorbatum 80, e 171, aqua purificata, propylenglycolum 420 mg, aromatica cum benzylis salicylas amylis cinnamaldehydum hydroxycitronellalum alcohol cinnamylicus isoeugenolum citronellolum eugenolum, propylis parahydroxybenzoas 7 mg, e 218 14 mg, materiale di supporto: polyesterum, ad praeparationem pro 140 cm². - antiflogistico - synthetika
olmesartan/amlodipin/hct mylan 20 mg - 5 mg - 12,5 mg filmtablette
mylan - olmesartan medoxomil; amlodipine besilate; hydrochlorothiazide - filmtablette - 20 mg - 5 mg - 12,5 mg - olmesartan medoxomil 20 mg; amlodipine besilate 6.95 mg; hydrochlorothiazide 12.5 mg - olmesartan medoxomil, amlodipine and hydrochlorothiazide